Abstract:Abstract Background The adverse reactions (ADRs) of targeted therapy were closely associated with treatment response, clinical outcome, quality of life (QoL) of patients with cancer. However, few studies presented the correlation between ADRs of targeted therapy and treatment effects among cancer patients. This study was to explore the characteristics of ADRs with targeted therapy and the prognosis of cancer patients based on the clinical data. Methods A retrospective secondary data analysis was conducted within an ADR data set including 2703 patients with targeted therapy from three Henan medical centers of China between January 2018 and December 2019. The significance was evaluated with chi-square test between groups with or without ADRs. Univariate and multivariate logistic regression with backward stepwise method were applied to assess the difference of pathological characteristics in patients with cancer. Using the univariate Cox regression method, the actuarial probability of overall survival was performed to compare the clinical outcomes between these two groups. Results A total of 485 patients were enrolled in this study. Of all patients, 61.0% ( n = 296) occurred ADRs including skin damage, fatigue, mucosal damage, hypertension and gastrointestinal discomfort as the top 5 complications during the target therapy. And 62.1% of ADRs were mild to moderate, more than half of the ADRs occurred within one month, 68.6% ADRs lasted more than one month. Older patients ( P = 0.022) and patients with lower education level ( P = 0.036), more than 2 comorbidities ( P = 0.021), longer medication time ( P = 0.022), drug combination ( P = 0.033) and intravenous administration ( P = 0.019) were more likely to have ADRs. Those with ADRs were more likely to stop taking ( P = 0.000), change ( P = 0.000), adjust ( P = 0.000), or not take the medicine on time ( P = 0.000). The number of patients with recurrence ( P = 0.000) and metastasis ( P = 0.006) were statistically significant difference between ADRs and non-ADRs group. And the patients were significantly poor prognosis in ADRs groups compared with non-ADRs group. Conclusion The high incidence of ADRs would affect the treatment and prognosis of patients with cancer. We should pay more attention to these ADRs and develop effective management strategies.

Analysis of risk factors of serious adverse drug reactions in chemotherapy of lung cancer patients

Clinical analysis of 1946 cases of adverse drug reactions associated with chemotherapy in cancer patients

Characteristics of Adverse Reactions of Antineoplastic Drugs in 787 Cases and the Prognosis Analysis

Influence factors of chemotherapy toxicities in breast cancer patients

Analysis of 422 cases adverse drug reactions of antineoplastic drugs

Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China

Clinical analysis of 273 adverse drug reaction reports of antineoplastics in our hospital

Analysis of 281 Adverse Drug Reaction Reports of Antineoplastics Drugs in Our Hospital

The incidence and risk factors of chemotherapy induced liver injury of the patients with gastrointestinal cancer adjuvant chemotherapy following radical surgery

Evaluation of adverse drug reactions of chemotherapeutic agents used in advanced non-small cell lung cancer – experience from a rural tertiary care institution in North Eastern India

The severity of adverse drug reactions and their influencing factors based on the ADR monitoring center of Henan Province

Prevention and Treatment Adverse Drug Reactions of Antitumor Medicines

Investigation of ADRs in Patients with SARS

Analysis of clinical and dosimetric factors associated with radiation pneumonitis in patients with lung cancer or esophageal cancer treated with intensity-modulated radiotherapy

Risk factors for acute exacerbation of interstitial lung disease during chemotherapy for lung cancer: a systematic review and meta-analysis

Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer

Clinical analysis of severe adverse drug reactions in Peking Union Hospital from 2013 to 2015

Analysis of Survival Data in Patients with Advanced Non-Small-Cell Lung Cancer Aged 60 Years and Over

[Analysis of Prognostic Factors in 541 Female Patients with Advanced Non-Small Cell Lung Cancer].

The Efficacy And Safety Of First-Line Chemotherapy In Patients With Non-Small Cell Lung Cancer And Interstitial Lung Disease: A Systematic Review And Meta-Analysis

Analysis of 56 Adverse Drug Reaction Cases Induced by Oxaliplatin in Our Hospital